Medtronic (NYSE:MDT) Updates FY25 Earnings Guidance

Medtronic (NYSE:MDT) issued an update on its FY25 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $5.44-5.50 for the period, compared to the consensus estimate of $5.45. Medtronic also updated its FY 2025 guidance to 5.440-5.500 EPS.

Analyst Ratings Changes

Several brokerages have recently issued reports on MDT. Piper Sandler raised their price objective on Medtronic from $85.00 to $90.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 21st. Barclays upped their price objective on shares of Medtronic from $104.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, August 22nd. UBS Group upgraded Medtronic from a “sell” rating to a “neutral” rating and increased their target price for the company from $76.00 to $90.00 in a research report on Thursday, August 15th. Wells Fargo & Company lifted their price objective on Medtronic from $105.00 to $106.00 and gave the stock an “overweight” rating in a report on Wednesday, August 21st. Finally, Robert W. Baird upped their target price on shares of Medtronic from $90.00 to $96.00 in a report on Friday. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Medtronic currently has an average rating of “Hold” and an average price target of $95.80.

Medtronic Trading Up 0.1 %

Shares of NYSE MDT opened at $87.64 on Tuesday. The stock has a fifty day simple moving average of $89.42 and a 200-day simple moving average of $84.82. Medtronic has a twelve month low of $74.66 and a twelve month high of $92.68. The stock has a market capitalization of $112.39 billion, a PE ratio of 29.61, a PEG ratio of 2.50 and a beta of 0.84. The company has a current ratio of 2.13, a quick ratio of 1.61 and a debt-to-equity ratio of 0.55.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, November 19th. The medical technology company reported $1.26 EPS for the quarter, topping the consensus estimate of $1.25 by $0.01. Medtronic had a net margin of 12.06% and a return on equity of 13.68%. The business had revenue of $8.40 billion during the quarter, compared to the consensus estimate of $8.27 billion. During the same quarter in the previous year, the firm posted $1.25 earnings per share. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. On average, equities analysts forecast that Medtronic will post 5.44 earnings per share for the current year.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.